ScripWhen clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around
Pink SheetThe US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti
ScripThe decision by iTeos Therapeutics to wind down operations just a couple of weeks after the failure of its anti-TIGIT antibody belrestotug rather than hold on to considerable cash reserves until a buy
ScripGSK intends to file for US approval of the oral carbapenem antibiotic tebipenem-HBr to treat complicated urinary tract infections (cUTI) during the second half of 2025, three years after Spero Therape